Clinical Trial Update: Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update reporting completed results for Posoleucel (ALVR105) studied to prevent multiple viral infections after allogeneic hematopoietic cell tran…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenovirus Infection
• Bk Virus Infection
• Cytomegalovirus Infections
• Epstein-barr Virus Infections
• Human Herpes Virus-6 Infection
• Jc Virus Infection

Drugs mentioned

• Posoleucel (Posoleucel)

Snippet

Sponsor: AlloVir | Conditions: Adenovirus Infection, BK Virus Infection | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2024-05-07